Abstract 3224: Targeted non-invasive therapy of prostate cancer using fusogenic liposomes

Abstract Prostate cancer is the most common cancer in Canadian men. Most chemotherapeutic drugs do not preferentially target the tumour and therefore subject the patient's healthy cells to significant toxicity. There is therefore an urgent need for a novel strategy to deliver chemotherapeutic drugs specifically to the tumour. P14 is a fusion associated small transmembrane (FAST) protein which mediates efficient cell-cell interaction. When we incorporate this p14 FAST protein into liposomes we increase the fusion of the liposome to cell membranes. I hypothesize that targeted ablation of prostate cancer may be achieved by delivering chemotherapeutics encapsulated inside fusogenic liposomes targeted to the gastrin releasing peptide receptors. The objectives of the study are to i) validate the fusogenic properties of p14-containg liposomes ii) express and purify p14-bomesin fusion protein, iii) assemble targeted fusogenic lipsoomes iv) and assess the targeted ablation of human prostate cancer in a xenograft model. To validate the fusogenic properties of p14-containing liposomes in our cell lines, we encapsulated fluorescent dextran inside liposomes containing either no p14, mutant p14 (fusogenic incompetent) or an active p14. We incubated the liposomes on human fibrosarcoma cells (HT1080) and measured the uptake of fluorescent dextran using fluorescent microscopy. To construct a fusion protein, we used PCR amplification to fuse bombesin to the C-terminus of the p14 protein. Our analysis demonstrates that the incorporation of the p14 protein significantly increased the fluorescent dextran uptake in the cytoplasm of the HT1080 cells compared to the liposomes that contained no p14 and the mutant p14. Protein purification of the p14-bombesin fusion protein is still in progress. I propose to use these targeted fusogenic liposomes for future studies to evaluate the ability of bombesin-coated fusogenic liposomes to target prostate cells in vitro and deliver a toxic therapeutic payload to prostate tumours in vivo and assess tumour reduction. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3224. doi:10.1158/1538-7445.AM2011-3224

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.